Form 8-K - Current report:
SEC Accession No. 0001193125-21-267358
Filing Date
2021-09-08
Accepted
2021-09-08 08:35:37
Documents
12
Period of Report
2021-09-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d228732d8k.htm   iXBRL 8-K 24280
  Complete submission text file 0001193125-21-267358.txt   146692

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alny-20210906.xsd EX-101.SCH 2887
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alny-20210906_lab.xml EX-101.LAB 18137
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alny-20210906_pre.xml EX-101.PRE 11404
5 EXTRACTED XBRL INSTANCE DOCUMENT d228732d8k_htm.xml XML 3382
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

EIN.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 211240811
SIC: 2834 Pharmaceutical Preparations